Literature DB >> 22082804

Aberrant expressions of leptin and adiponectin receptor isoforms in chronic myeloid leukemia patients.

Kamile Ozturk1, Ferit Avcu, A Ugur Ural.   

Abstract

BACKGROUND: Leptin and adiponectin receptors mediate the role of leptin in stimulating the growth of leukemic cells and the protective function of adiponectin undertaken in several malignancies such as leukemia. In this study, we investigated the involvement of the expression of leptin and adiponectin receptors in chronic myeloid leukemia (CML) pathogenesis.
METHODS: The expression of leptin receptor isoforms, OB-Rt, OB-Ra, and OB-Rb, and the expression of adiponectin receptors, AdipoR1 and AdipoR2, were measured as mRNA levels in two CML cell lines (K562 and Meg-01) and 20 CML patients and 24 healthy controls by using RT-PCR.
RESULTS: OB-Rt and OB-Ra isoforms expression of the leptin receptors were found to be significantly lower in Meg-01 cell lines than K562 cells. All leptin receptors were downregulated in CML patients and more particularly OB-Rb level was found to be undetectably low in normal PBMC as well as in CML patients. AdipoR1 expression level was higher in Meg-01 than in K562, whereas AdipoR2 level was found to be unchanged in both cell lines. Interestingly, while AdipoR1 expression increased in CML patients, AdipoR2 decreased. Moreover, imatinib therapy did not affect both leptin and adiponectin isoform expressions.
CONCLUSION: While the decrease in leptin receptor levels in CML patients was confirmed, the increase in AdipoR1 levels and relevant decrease in AdipoR2 levels depicted their possible involvement in CML pathogenesis. This suggests different functions of adiponectin receptors in CML development.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22082804     DOI: 10.1016/j.cyto.2011.10.004

Source DB:  PubMed          Journal:  Cytokine        ISSN: 1043-4666            Impact factor:   3.861


  12 in total

1.  Adiponectin enhances Imatinib anti-tumour activity in human chronic myeloid leukaemia cells with serum levels associated with Imatinib efficacy in early chronic phase patients.

Authors:  Guangshan Tan; Lei Shi; Qiang Li; Mingjun Wang
Journal:  Cell Prolif       Date:  2015-08       Impact factor: 6.831

Review 2.  The role of adiponectin in cancer: a review of current evidence.

Authors:  Maria Dalamaga; Kalliope N Diakopoulos; Christos S Mantzoros
Journal:  Endocr Rev       Date:  2012-04-30       Impact factor: 19.871

3.  Leptin receptor, a surface marker for a subset of highly engrafting long-term functional hematopoietic stem cells.

Authors:  Thao Trinh; James Ropa; Arafat Aljoufi; Scott Cooper; Anthony Sinn; Edward F Srour; Hal E Broxmeyer
Journal:  Leukemia       Date:  2020-11-07       Impact factor: 11.528

Review 4.  Leptin and its receptor in hematologic malignancies.

Authors:  Tian-Jie Han; Xin Wang
Journal:  Int J Clin Exp Med       Date:  2015-11-15

5.  Development of second generation peptides modulating cellular adiponectin receptor responses.

Authors:  Laszlo Otvos; Daniel Knappe; Ralf Hoffmann; Ilona Kovalszky; Julia Olah; Tim D Hewitson; Roma Stawikowska; Maciej Stawikowski; Predrag Cudic; Feng Lin; John D Wade; Eva Surmacz; Sandor Lovas
Journal:  Front Chem       Date:  2014-10-17       Impact factor: 5.221

6.  CD36 defines primitive chronic myeloid leukemia cells less responsive to imatinib but vulnerable to antibody-based therapeutic targeting.

Authors:  Niklas Landberg; Sofia von Palffy; Maria Askmyr; Henrik Lilljebjörn; Carl Sandén; Marianne Rissler; Satu Mustjoki; Henrik Hjorth-Hansen; Johan Richter; Helena Ågerstam; Marcus Järås; Thoas Fioretos
Journal:  Haematologica       Date:  2017-12-28       Impact factor: 9.941

7.  Association between adipokines and thyroid carcinoma: a meta-analysis of case-control studies.

Authors:  Junyu Zhao; Jing Wen; Shengnan Wang; Jinming Yao; Lin Liao; Jianjun Dong
Journal:  BMC Cancer       Date:  2020-08-20       Impact factor: 4.430

8.  Role of adiponectin and its receptors in cancer.

Authors:  Stephanie Obeid; Lionel Hebbard
Journal:  Cancer Biol Med       Date:  2012-12       Impact factor: 4.248

9.  Association of differential gene expression with imatinib mesylate and omacetaxine mepesuccinate toxicity in lymphoblastoid cell lines.

Authors:  Hemant Kulkarni; Harald H H Göring; Vincent Diego; Shelley Cole; Ken R Walder; Greg R Collier; John Blangero; Melanie A Carless
Journal:  BMC Med Genomics       Date:  2012-08-23       Impact factor: 3.063

10.  Leptin modification in chronic myeloid leukemia patients treated with imatinib: An emerging effect of targeted therapy.

Authors:  Stefania Mariani; Sabrina Basciani; Fiorina Giona; Carla Lubrano; Salvatore Ulisse; Lucio Gnessi
Journal:  Leuk Res Rep       Date:  2013-08-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.